Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00673751
Recruitment Status : Unknown
Verified May 2008 by Glostrup University Hospital, Copenhagen.
Recruitment status was:  Enrolling by invitation
First Posted : May 7, 2008
Last Update Posted : May 7, 2008
Information provided by:
Glostrup University Hospital, Copenhagen

Brief Summary:
The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome

Condition or disease Intervention/treatment Phase
Short Bowel Syndrome Drug: GLP-2 Drug: Placebo Not Applicable

Detailed Description:
previous studies have shown that GLP-2 increases mesenteric blow flow, we wish to examine the effect of subcutaneus GLP-2 on patients with short bowl syndrome. The patients will single blinded been given 450 nmol GLP-2 and isotonic saline in order to act as their own reference.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: 2
subcutaneous isotonic saline
Drug: Placebo
Active Comparator: 1
subcutaneous GLP-2
Drug: GLP-2
450 nmol subcutaneous

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnose of short bowel syndrome 4 month of stable fase

Exclusion Criteria:

  • activity in IBD

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00673751

Glostrup University Hospital
Glostrup, Region Hovedstaden, Denmark, 2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen

Responsible Party: Lasse Bremholm, Dept. of gastroenterology, Glostrup Hospital, University of Copenhagen Identifier: NCT00673751     History of Changes
Other Study ID Numbers: H-A-2008-032
First Posted: May 7, 2008    Key Record Dates
Last Update Posted: May 7, 2008
Last Verified: May 2008

Keywords provided by Glostrup University Hospital, Copenhagen:
mesenteric blood flow
short bowel syndrome
Glucagon-Like Peptide 2

Additional relevant MeSH terms:
Short Bowel Syndrome
Pathologic Processes
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Postoperative Complications
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs